These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 20535651)

  • 1. Oncogenic mutations of PIK3CA in human cancers.
    Samuels Y; Waldman T
    Curr Top Microbiol Immunol; 2010; 347():21-41. PubMed ID: 20535651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human tumor mutants in the p110alpha subunit of PI3K.
    Liu Z; Roberts TM
    Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic mutations of PIK3CA in human cancers.
    Samuels Y; Velculescu VE
    Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
    Ligresti G; Militello L; Steelman LS; Cavallaro A; Basile F; Nicoletti F; Stivala F; McCubrey JA; Libra M
    Cell Cycle; 2009 May; 8(9):1352-8. PubMed ID: 19305151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic PI3K and its role in cancer.
    Samuels Y; Ericson K
    Curr Opin Oncol; 2006 Jan; 18(1):77-82. PubMed ID: 16357568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
    APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of PIK3CA in gastric adenocarcinoma.
    Li VS; Wong CW; Chan TL; Chan AS; Zhao W; Chu KM; So S; Chen X; Yuen ST; Leung SY
    BMC Cancer; 2005 Mar; 5():29. PubMed ID: 15784156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene of the month: PIK3CA.
    Lai K; Killingsworth MC; Lee CS
    J Clin Pathol; 2015 Apr; 68(4):253-7. PubMed ID: 25688137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
    Kozaki K; Imoto I; Pimkhaokham A; Hasegawa S; Tsuda H; Omura K; Inazawa J
    Cancer Sci; 2006 Dec; 97(12):1351-8. PubMed ID: 17052259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PIK3CA gene is mutated with high frequency in human breast cancers.
    Bachman KE; Argani P; Samuels Y; Silliman N; Ptak J; Szabo S; Konishi H; Karakas B; Blair BG; Lin C; Peters BA; Velculescu VE; Park BH
    Cancer Biol Ther; 2004 Aug; 3(8):772-5. PubMed ID: 15254419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Characterization of a Novel Constitutional PIK3CA Mutation in a Child Lacking the Typical Segmental Overgrowth of "PIK3CA-Related Overgrowth Spectrum".
    Di Donato N; Rump A; Mirzaa GM; Alcantara D; Oliver A; Schrock E; Dobyns WB; O'Driscoll M
    Hum Mutat; 2016 Mar; 37(3):242-5. PubMed ID: 26593112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.
    VanLandingham NK; Nazarenko A; Grandis JR; Johnson DE
    Adv Biol Regul; 2023 Jan; 87():100934. PubMed ID: 36402737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
    Dirican E; Akkiprik M; Özer A
    Tumour Biol; 2016 Jun; 37(6):7033-45. PubMed ID: 26921096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI 3-kinases: hidden potentials revealed.
    Vogt PK; Bader AG; Kang S
    Cell Cycle; 2006 May; 5(9):946-9. PubMed ID: 16687927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.
    Rudd ML; Price JC; Fogoros S; Godwin AK; Sgroi DC; Merino MJ; Bell DW
    Clin Cancer Res; 2011 Mar; 17(6):1331-40. PubMed ID: 21266528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.